Jazz Pharmaceuticals shared on LinkedIn:
“We reported our third quarter 2026 results today, reflecting continued progress across our commercial and R and D portfolio.
We expanded our rare epilepsy portfolio through the acquisition of Actio Biosciences and offered patients living with first-line HER2+ gastroesophageal adenocarcinoma a new treatment option.
Our work is measured by the difference it makes for patients. We’re grateful to our employees, collaborators and patients helping us deliver on that promise.
View our Q3 results.”
Key Highlights
Third Quarter 2026 Financial Results
- Broad commercial execution drives record quarterly revenues of $1.2 billion (+10% YoY).
- Strong early launch in first-line HER2+ advanced GEA.
- Company raises full year 2026 total revenue guidance.
- Closed Actio acquisition, adding ABS-1230 (JZP6979) to rare epilepsy.
Read more articles about Jazz Pharmaceuticals on OncoDaily.
